Is the price fair?
What TGTX's price assumes
TG Therapeutics, Inc. trades at 20.3× earnings against 31.5× for the median Biotechnology name, cheaper than its own group.
20.3
Trailing P/E · Biotechnology median 31.5 · cheaper than the typical name in its group
- Price / sales
- 7.59
Price / sales · as of 2026-Q1
- Free cash flow yield
- 0.21%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +50%
Growth the price implies · The price pays for +50% free cash flow growth a year for a decade; revenue has grown +222% a year over the last three.
Details›
- Price / book2026-Q1
- 9.12
- EV / EBIT2026-Q1
- 37.6
- EV / sales2026-Q1
- 8.02
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $17M
- Market capitalisation
- $8.21B
- 3-year revenue growth
- +222%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.